12 月 24 日,CDE 官网显示,和黄医药酒石酸凡瑞格拉替尼片上市申请获得受理。此前,该药已被 CDE 纳入优先审评,适应症为:用于既往接受过系统性治疗且经检测确认存在有 FGFR2 融合或重排的晚期、转移性或不可手术切除的肝内胆管癌(ICC)成人患者的治疗。截图来源:CDE 官网根据和黄医药公开资料,Insight 数据库推测凡瑞格拉替尼是和黄医药开发的在研1 类新药 ...
Source Link12 月 24 日,CDE 官网显示,和黄医药酒石酸凡瑞格拉替尼片上市申请获得受理。此前,该药已被 CDE 纳入优先审评,适应症为:用于既往接受过系统性治疗且经检测确认存在有 FGFR2 融合或重排的晚期、转移性或不可手术切除的肝内胆管癌(ICC)成人患者的治疗。截图来源:CDE 官网根据和黄医药公开资料,Insight 数据库推测凡瑞格拉替尼是和黄医药开发的在研1 类新药 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.